Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study

2015 ◽  
Vol 76 (6) ◽  
pp. 1267-1272 ◽  
Author(s):  
Young Saing Kim ◽  
Sun Jin Sym ◽  
Min Young Baek ◽  
Inkeun Park ◽  
Junshik Hong ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Pilot Study ◽  
Advanced Gastric Cancer ◽  
Low Dose ◽  
Line Treatment ◽  
First Line ◽  
Her2 Positive ◽  
First Line Treatment

scholarly journals Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

2019 ◽  
Vol 84 (6) ◽  
pp. 1365-1365
Author(s):  
Fernando Rivera ◽  
C. Romero ◽  
P. Jimenez-Fonseca ◽  
M. Izquierdo-Manuel ◽  
A. Salud ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
Her2 Positive ◽  
First Line Treatment

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine.

Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer

2020 ◽  
pp. 030089162096982
Author(s):  
Mustafa Gürbüz ◽  
Erman Akkuş ◽  
Abdullah Sakin ◽  
Semiha Urvay ◽  
Atike Gökçen Demiray ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Gastric Adenocarcinoma ◽  
Locally Advanced ◽  
Line Treatment ◽  
First Line ◽  
Standard Chemotherapy ◽  
Her2 Positive ◽  
Intensified Chemotherapy ◽  
First Line Treatment

Purpose: Taxane-containing combinations are recommended for the first-line therapy of advanced gastric cancer. It is not known which chemotherapy regimen is the best with trastuzumab for HER2-positive patients. The aim of this study was to compare taxane-containing intensified chemotherapy versus standard chemotherapy in combination with trastuzumab in the first-line treatment of HER2-positive advanced gastric adenocarcinoma. Methods: This study is a retrospective multicenter study of the Turkish Oncology Group. A total of 130 HER2-positive patients with inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma being given chemotherapy plus trastuzumab as the first-line treatment were included from 16 different oncology centers. Trastuzumab combination with intensified chemotherapy including taxane or standard chemotherapy was compared in terms of progression-free survival (PFS), overall survival (OS), and toxicity. Results: There were 108 patients in the standard and 22 patients in the intensified chemotherapy group. PFS of the standard and intensified group were 5.6 months (95% confidence interval [CI] 4.8–6.4) and 5.3 months (95% CI 2.6–8), respectively ( p = 0.70). OS of the standard and intensified group were 11.1 months (95% CI 8.3–13.9) and 15.2 months (95% CI 12.7–17.7), respectively ( p = 0.03). Repeated analysis excluding patients given any previous therapy revealed similar results. The intensified group had more fever and febrile neutropenia. Conclusion: Trastuzumab combination with intensified chemotherapy provides better OS in first-line treatment of HER2-positive advanced gastric cancer. Further large-scale studies should be performed in HER2-positive patients.

scholarly journals A Retrospective Analysis of First-Line Treatment in HER2-Positive and HER2-Negative Advanced Gastric Cancer

2013 ◽  
Vol 24 ◽  
pp. ix66
Author(s):  
K. Onodera ◽  
K. Kawakami ◽  
S. Yukisawa ◽  
E. Warita ◽  
Y. Yamanaka
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Retrospective Analysis ◽  
Line Treatment ◽  
First Line ◽  
Her2 Positive ◽  
First Line Treatment

scholarly journals A Retrospective Study of Pegylated Liposomal Doxorubicin Combined with S-1 and Low-dose Oxaliplatin as First-Line Treatment for Advanced Gastric Cancer

2020 ◽  
Author(s):  
Jian Ma ◽  
Quanliang Yang ◽  
Yanzhi Bi ◽  
Min Xiao ◽  
Xiaoqian Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Advanced Gastric Cancer ◽  
Low Dose ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Drug Regimen ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Abstract Background: At present, the first-line treatment of advanced gastric cancer is oxaliplatin combined with fluorouracil (capecitabine or S-1). Is there a three-drug regimen in which the curative effect is higher than that of the two-drug regimen, but the side effects are not significantly increased? This retrospective study evaluated the efficacy and side effects of pegylated liposomal doxorubicin (PLD) combined with S-1 and low-dose oxaliplatin as first-line treatment for advanced gastric cancer.Methods: Advanced gastric cancer patients who received PLD combined with S-1 and low-dose oxaliplatin (D-SOX) or standard SOX as first-line chemotherapy from Jan 2015 to Dec 2018 were included in the study. Overall survival (OS), progression-free survival (PFS), response rate (RR), and safety were assessed. Results: A total of 52 patients were included in this study. There were 23 cases in D-SOX group and 29 cases in SOX group. The median PFS was 7.1 months (95% CI 5.66–8.54 months) in the SOX group and 9.1 months (95% CI 4.2–14.0 months) in the D-SOX group (P=0.036). The median OS was 12.5 months (95% CI 7.31–17.70 months) in the SOX group and 19.5 months (95% CI 16.23–22.7 months) in the D-SOX group (P=0.017). The incidence of treatment-related grade III-IV adverse events was no more than 10%. The incidence of neurotoxicity was significantly reduced in the D-SOX group.Conclusions: This study suggests that PLD combined with S-1 and low-dose oxaliplatin might be a safe and more effective treatment for advanced gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document